Eagle Pharmaceuticals Announces Divestiture of Barhemsys

Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on January 14, 2026 the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, Paris.

Rhea-AI Summary

Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on January 14, 2026 the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, Paris. Barhemsys, approved by the FDA in February 2020 and launched in the U.S. in November 2020, is described as the only FDA-approved treatment for postoperative nausea and vomiting (PONV). Eagle said cash proceeds will be used for ongoing business operations. LXO said it will deploy a direct hospital sales force for Barhemsys, aiming to create synergies with its U.S. portfolio and shared distribution channels.

Positive

• Divestiture completed of U.S. marketing authorization to LXO Group
• Barhemsys approved Feb 2020 and launched Nov 2020
• Proceeds earmarked for Eagle’s ongoing business operations

Negative

• Loss of U.S. marketing rights for Barhemsys
• Future Barhemsys revenue will accrue to LXO, not Eagle

Argus Jan 14 session

+149.93% close to close Open Argus

Details

News Market Reaction – EGRX

In the Jan 14 session, EGRX gained 149.93%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +149.9% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +149.9% in the session following this news. A strong positive reaction aligns with a market that often focuses on balance-sheet and portfolio simplification events. The Barhemsys divestiture shifts Eagle away from a single branded asset and could be viewed as a step in refocusing its acute care strategy. However, the stock’s position at 0.34005, well below the 4.169 52-week high and the 1.48 200-day MA, highlights past pressure. Investors would need to weigh execution on core assets and use of divestiture proceeds.

Key Figures

Share price: $0.34005 52-week high: $4.169 52-week low: $0.0025 +5 more

Share price

$0.34005

Pre-news trading level for EGRX

52-week high

$4.169

Upper end of 52-week trading range

52-week low

$0.0025

Lower end of 52-week trading range

Market cap

$26,564,365

Equity value before Barhemsys divestiture news

Shares outstanding

13,157,754

As reported for 2025 annual meeting

Shares represented

10,769,820 (~82%)

Participation at 2025 annual meeting

Broker non-votes

1,064,408

2025 annual meeting voting breakdown

Rights plan exercise price

$20.00

Per Right under stockholder rights plan

Historical Context

5 past events · Latest: Oct 30

5 events

1. Oct 30

   Rights plan extension

   24h Move

   +0.0%

   Extended limited-duration stockholder rights plan to October 30, 2026.

2. Oct 21

   Annual meeting results

   24h Move

   +0.0%

   Reported 2025 annual meeting outcomes and director elections.

3. Oct 15

   Q2 2025 statements

   24h Move

   -14.0%

   Announced availability of unaudited Q2 2025 financial statements.

4. Oct 06

   Q1 2025 statements

   24h Move

   -46.7%

   Posted unaudited Q1 2025 financial statements online.

5. Sep 17

   Proxy & audits

   24h Move

   -17.9%

   Released proxy materials and 2023–2024 audited financials ahead of 2025 meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

postoperative nausea and vomiting, ponv, amisulpride, antiemetic, +1 more

5 terms

postoperative nausea and vomiting medical

"Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV)..."

Postoperative nausea and vomiting (PONV) is the nausea and vomiting patients may experience after a surgical procedure, commonly within the first day, often triggered by anesthesia, pain, opioids or other medications. It matters to investors because high PONV rates can lengthen hospital stays, increase treatment costs, and boost demand for anti-nausea drugs or improved anesthesia products — like a factory slowdown that reduces output and raises operating expenses.

ponv medical

"Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV)..."

Postoperative nausea and vomiting (PONV) is the feeling of nausea and episodes of vomiting that can occur after surgery, often triggered by anesthesia, pain medication, or the surgery itself; think of it like motion sickness that happens when the body is recovering from a medical procedure. It matters to investors because PONV affects patient comfort, recovery time and hospital costs, driving demand for effective drugs, devices or protocols and influencing clinical trial outcomes and reimbursement decisions.

amisulpride medical

"divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S."

An antipsychotic medication used to treat conditions such as schizophrenia and certain forms of depression by adjusting levels of brain chemicals that affect mood and thinking. Think of it like a thermostat for brain signaling: it aims to reduce excessive or erratic activity that causes hallucinations, delusions, or severe low mood. For investors, study outcomes, regulatory approvals, safety reports, patent status, or changes in prescribing can directly affect a drug maker’s revenue prospects and stock risk.

antiemetic medical

"alone or with another antiemetic in patients with or without prior prophylaxis."

An antiemetic is a medication that helps prevent or relieve nausea and vomiting. It is commonly used in medical settings to keep patients comfortable during treatments like chemotherapy or surgery. For investors, understanding antiemetics can be relevant because companies that produce these drugs may be affected by healthcare trends, regulatory changes, or advances in medical research.

fda-approved regulatory

"Barhemsys is the only FDA-approved treatment for PONV..."

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.

Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or with another antiemetic in patients with or without prior prophylaxis. Approved in February 2020 and launched in the U.S. in November 2020, Barhemsys is the only FDA-approved treatment for PONV, addressing a critical need in post-surgical care by offering a targeted, effective option to manage this common complication.

“This strategic divestiture reflects Eagle Pharmaceuticals commitment to streamlining its acute care business and maximizing value for our shareholders, while ensuring access to this important treatment for the millions of patients affected annually by PONV,” stated Michael Graves, CEO of Eagle.

“The deployment of a direct hospital sales force around Barhemsys significantly enhances our US commercial capabilities and creates immediate synergies with our existing U.S. portfolio, with all products being distributed in the same distribution channel,” said Jason Jones, Head of U.S. Operations at LXO Group.

Cash from the divestiture will be used for Eagle’s ongoing business operations.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY^®, RYANODEX^®, BENDEKA^®, BELRAPZO^®, TREAKISYM^® (Japan), and BYFAVO^® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations Contact

Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eagle Pharmaceuticals announce on January 14, 2026 regarding Barhemsys (EGRX)?

Eagle announced the divestiture of the U.S. marketing authorization for Barhemsys to LXO Group.

When was Barhemsys (EGRX) FDA approved and launched in the U.S.?

Barhemsys was FDA approved in February 2020 and launched in the U.S. in November 2020.

How will Eagle use the cash from the Barhemsys divestiture (EGRX)?

Eagle said cash proceeds will be used for the company’s ongoing business operations.

What will LXO Group do with Barhemsys after acquiring U.S. rights from Eagle (EGRX)?

LXO plans to deploy a direct hospital sales force and align Barhemsys with its U.S. distribution channels.

Does Eagle retain any U.S. marketing rights to Barhemsys after the deal (EGRX)?

No — Eagle divested the U.S. marketing authorization for Barhemsys to LXO Group.